Projected effectiveness of dapagliflozin in heart failure with reduced ejection fraction in clinical practice supplementary table

Aim: To estimate the projected effectiveness of dapagliflozin in subjects with heart failure (HF) with reduced ejection fraction in clinical practice in Spain. Materials & methods: This multicenter cohort study included subjects aged 50 years or older consecutively hospitalized for HF in internal medicine departments in Spain. The projected clinical benefits of dapagliflozin were estimated based on results from the DAPA-HF trial. Results: A total of 1595 patients were enrolled, of whom 1199 (75.2%) were eligible for dapagliflozin. Within 1 year after discharge, 21.6% of patients eligible for dapagliflozin were rehospitalized for HF and 20.5% died. Full implementation of dapagliflozin led to an absolute risk reduction of 3.5% for mortality (number needed to treat = 28) and 6.5% (number needed to treat = 15) for HF readmission. Conclusion: Treatment with dapagliflozin in clinical practice may markedly reduce mortality and readmissions for HF.

研究目的：评估达格列净（dapagliflozin）在西班牙临床实践中用于射血分数降低型心力衰竭（heart failure with reduced ejection fraction, HF）患者的预估临床疗效。材料与方法：本多中心队列研究纳入了西班牙各内科病房因心力衰竭连续收治的50岁及以上心力衰竭受试者。本研究依托DAPA-HF临床试验的研究数据，对达格列净的预估临床获益进行量化评估。结果：本研究共纳入1595例患者，其中1199例（75.2%）符合达格列净的治疗适应证。在出院后1年内，符合治疗指征的患者中，21.6%因心力衰竭再次住院，20.5%死亡。全面规范应用达格列净可使全因死亡率绝对风险降低3.5%（需治疗人数=28），心力衰竭再住院风险绝对降低6.5%（需治疗人数=15）。结论：临床实践中采用达格列净进行治疗，可显著降低心力衰竭患者的死亡率及再住院风险。